ARGO: A RANDOMISED PHASE II STUDY OF ATEZOLIZUMAB WITH RITUXIMAB, GEMCITABINE AND OXALIPLATIN IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA WHO ARE NOT CANDIDATES FOR HIGH‐DOSE THERAPY
Sign Up to like & getrecommendations! Published in 2019 at "Hematological Oncology"
DOI: 10.1002/hon.1_2632
Abstract: Roche, Janssen, Takeda, MSD, Gilead, Bristol Myers Squibb, AstraZenecca; Research Funding: Celgene, Roche, Abbvie; Other Remuneration: Roche, Amgen. Chu, M: Honoraria: AstraZeneca, Gilead, Celgene. Dreyling, M: Honoraria: Bayer, Celgene, Gilead, Janssen, Roche, Acerta, Bayer, Celgene,… read more here.
Keywords: janssen; roche; research funding; celgene ... See more keywords
PODCAST: First rounders: Christoph Lengauer
Sign Up to like & getrecommendations! Published in 2018 at "Nature Biotechnology"
DOI: 10.1038/nbt1118-1030b
Abstract: In an unusual move, Gilead Sciences said in September that it will sell generic versions of its own hepatitis C virus (HCV) drugs in the US through a subsidiary, Asegua Therapeutics. These ‘authorized generics’ will… read more here.
Keywords: first rounders; rounders christoph; gilead; market ... See more keywords
P210 Efficacy and safety of filgotinib for patients with RA with inadequate response to methotrexate: FINCH1 primary outcome results
Sign Up to like & getrecommendations! Published in 2020 at "Rheumatology"
DOI: 10.1093/rheumatology/keaa111.205
Abstract: Filgotinib (FIL) is an oral, potent, selective Janus kinase 1 inhibitor that has shown good efficacy and was well tolerated for treatment of rheumatoid arthritis (RA). The objective of this study was to evaluate efficacy… read more here.
Keywords: gilead sciences; shareholder; sciences inc; gilead ... See more keywords
THU0194 SELECTIVE INHIBITION OF JANUS KINASE 1 (JAK1) BY FILGOTINIB MODULATES THE DISEASE-ASSOCIATED WHOLE BLOOD TRANSCRIPTIONAL PROFILE OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS
Sign Up to like & getrecommendations! Published in 2019 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2019-eular.2509
Abstract: Background Filgotinib (FIL), an oral selective JAK1 inhibitor, was safe and efficacious in FINCH2, a randomized, double-blind, placebo-controlled, phase 3 study in patients with active rheumatoid arthritis (RA) who had an inadequate response to biologic… read more here.
Keywords: gilead sciences; sciences inc; gilead; fil ... See more keywords
FRI0139 FILGOTINIB PROVIDED RAPID AND SUSTAINED RELIEF OF PAIN AND FATIGUE AND IMPROVED HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO BIOLOGIC DMARDS: RESULTS FROM THE FINCH 2 STUDY
Sign Up to like & getrecommendations! Published in 2020 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2020-eular.2901
Abstract: Background: EULAR guidelines recommend a treat-to-target approach focusing on reducing inflammation to prevent joint damage, physical disability, and mortality.1 However, patients consider reduction in pain and fatigue, along with maintenance of physical function, and improvement… read more here.
Keywords: fatigue; pain; gilead sciences; sciences inc ... See more keywords
OP0224 FILGOTINIB TREATMENT LEADS TO RAPID AND SUSTAINED REDUCTIONS IN INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATE TO SEVERE PSORIATIC ARTHRITIS
Sign Up to like & getrecommendations! Published in 2020 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2020-eular.4927
Abstract: Background: Psoriatic arthritis (PsA) is a chronic inflammatory musculoskeletal disease characterized by musculoskeletal and cutaneous inflammation. In the recent EQUATOR study (NCT03101670), patients (pts) with active PsA receiving the oral, selective Janus kinase 1 (JAK1)… read more here.
Keywords: gilead sciences; sciences inc; disease; employee ... See more keywords
Gilead Buys into Tizona's Anti-HLA-G Strategy.
Sign Up to like & getrecommendations! Published in 2020 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-nb2020-077
Abstract: Gilead announced plans in July to pay $300 million for a 49.9% stake in Tizona Therapeutics, with the option to buy the rest of the company for $1.25 billion. Whether Gilead follows through with the… read more here.
Keywords: buys tizona; gilead; gilead buys; hla strategy ... See more keywords